Description

2-[18F]Fluoro-2-Deoxy-β-D-Glucopyranose is a positron-emitting radiopharmaceutical agent, more commonly known as [18F]FDG. This compound is the cornerstone of modern diagnostic imaging, enabling the non-invasive visualization of metabolic activity in tissues. It is primarily utilized in positron emission tomography (PET) scans for oncology, neurology, and cardiology applications. Global suppliers and research institutions require a reliable source of this critical tracer to support advanced medical diagnostics and research.

Application

• Oncology Diagnostics: Primary application for detecting, staging, and monitoring the response to therapy in various cancers by highlighting regions of high glucose metabolism.
• Neurological Imaging: Used in PET scans to assess brain function, localize epileptic foci, and aid in the diagnosis of dementia and other neurodegenerative disorders like Alzheimer's disease.
• Cardiology: Employed to evaluate myocardial viability and perfusion in patients with coronary artery disease, helping to distinguish between scarred and hibernating heart tissue.
• Infectious Disease & Inflammation: Useful for localizing sites of infection or inflammation, such as in cases of fever of unknown origin or sarcoidosis.
• Clinical Research: Serves as a vital tool in pharmaceutical development for evaluating drug efficacy and in translational research studies.
• Radiopharmaceutical Synthesis: Acts as the final formulated product for direct clinical use or as a reference standard in quality control laboratories.

Basic Information

Product Name	2-[18F]Fluoro-2-Deoxy-β-D-Glucopyranose
CAS No.	105851-18-1
Molecular Formula	C6H11FO5
Molecular Weight	182.15 g/mol (non-radioactive analog)
Synonyms	[18F]FDG; Fluorodeoxyglucose F18; Fludeoxyglucose (18F); 2-Fluoro-2-deoxy-D-glucose (18F); FDG-18; 18F-FDG; Fludeoxyglucose F 18; Fludeoxyglucose F-18
EINECS	Contact for details

Quality Control

Every batch of 2-[18F]Fluoro-2-Deoxy-β-D-Glucopyranose ([18F]FDG) is manufactured and released in compliance with current Good Manufacturing Practice (cGMP) guidelines for radiopharmaceuticals. Quality assurance includes rigorous testing for radiochemical purity, radionuclidic purity, chemical purity, sterility, and apyrogenicity as per USP and Ph. Eur. monographs. A comprehensive Certificate of Analysis (COA), detailing all release specifications and the specific activity at the time of calibration, is provided with each shipment.

Storage

Preserve in a tightly closed container, protected from light. This radiopharmaceutical is supplied as a sterile, pyrogen-free solution. Store at controlled room temperature or as specified on the vial label. Due to the short half-life of Fluorine-18 (~110 minutes), product must be used promptly after receipt and in accordance with local radiation safety protocols.

Specification

Item	Specification
Appearance	Clear, colorless solution
Identification (HPLC)	Conforms to reference standard
Radiochemical Purity (HPLC)	≥ 95.0%
Radionuclidic Purity (Gamma Spectroscopy)	≥ 99.9%
Chemical Purity (HPLC)	Kryptofix 222 ≤ 50 µg/mL; 2-Deoxy-2-chloro-D-glucose ≤ 1 µg/mL
pH	4.5 - 7.5
Sterility Test	Sterile
Bacterial Endotoxins	< 175 EU/V (maximum administered dose)
Specific Activity	Reported at time of calibration (COA)

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.